VA
ALGS icon

VR Adviser’s Aligos Therapeutics ALGS Stock Holding History

VR Adviser’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-16,335
Closed -$8.32M – 28
2021
Q2 		$8.32M Hold
16,335
– – 1.01% 24
2021
Q1 		$9.29M Buy
16,335
+139
+0.9% +$92.5K 1.01% 22
2020
Q4 		$11.2M Buy
+16,196
New +$7.89M 1.65% 17

Other funds holding ALGS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

VR Adviser's ALGS Position: Q3 2021 in Review

VR Adviser sold out of Aligos Therapeutics (ALGS) in Q3 2021, closing a stake of 16,335 shares — an estimated $8.32M sold.

VR Adviser first reported a position in ALGS in Q4 2020 and held it in 3 quarters. The position peaked at $11.2M in Q4 2020. 68 funds tracked by Wall St. Rank hold ALGS as of Q3 2021.

  • VR Adviser reported no remaining Aligos Therapeutics position as of Q3 2021 after selling out during the quarter.
  • VR Adviser sold 16,335 Aligos Therapeutics shares in Q3 2021, an estimated $8.32M.
  • VR Adviser first reported a position in Aligos Therapeutics in Q4 2020 and held it in 3 quarters.
  • VR Adviser's Aligos Therapeutics position peaked at $11.2M in Q4 2020.
  • 68 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q3 2021.

Based on VR Adviser's 13F filing for Q3 2021, filed 15 Nov 2021.